Florilglutamic acid F-18

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Florilglutamic acid F-18
Accession Number
DB15041
Description

Florilglutamic acid F-18 is under investigation in clinical trial NCT02370563 (PET Imaging of Intracranial Cancers With 18F-FSPG).

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 206.204
Monoisotopic: 206.093220602
Chemical Formula
C8H14FNO4
Synonyms
  • 18F-FSPG

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Categories

Drug Categories
Not Available
Classification
Not classified

Chemical Identifiers

UNII
92T1Y5X038
CAS number
1196963-74-2
InChI Key
MKDNDKMECWBLOF-XUCPOOORSA-N
InChI
InChI=1S/C8H14FNO4/c9-3-1-2-5(7(11)12)4-6(10)8(13)14/h5-6H,1-4,10H2,(H,11,12)(H,13,14)/t5-,6-/m0/s1/i9-1
IUPAC Name
(2S,4S)-2-amino-4-[3-(¹⁸F)fluoropropyl]pentanedioic acid
SMILES
N[[email protected]@H](C[[email protected]](CCC[18F])C(O)=O)C(O)=O

References

General References
Not Available
ChemSpider
32698684

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedDiagnosticB-Cell Neoplasm / Estrogen Receptor Negative / HER2/Neu Negative / Metastatic Renal Cell Cancer / Progesterone Receptor Negative / Stage III Mesothelioma / Stage III Renal Cell Cancer / Stage IIIA Breast Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer / Stage IV Mesothelioma / Stage IV Non-Small Cell Lung Cancer / Stage IV Renal Cell Cancer / Triple-Negative Breast Carcinoma1
2RecruitingDiagnosticCardiac Sarcoidosis / Myocardial Inflammation1
2RecruitingDiagnosticCigarette Smoking Behavior / Lung, Carcinoma / Solitary Pulmonary Nodules1
2SuspendedDiagnosticCigarette Smokers / Current Smokers / Former Smoker / Multiple Pulmonary Nodules / Pulmonary Nodules1
1SuspendedDiagnosticAdult Hepatocellular Carcinoma / Benign Liver Tumor / Cholangiocarcinomas / Hepatic Metastases / Resectable Hepatocellular Carcinoma1
1TerminatedDiagnosticBrain Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility19.2 mg/mLALOGPS
logP-3ALOGPS
logP-2.4ChemAxon
logS-1ALOGPS
pKa (Strongest Acidic)2.22ChemAxon
pKa (Strongest Basic)9.53ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area100.62 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity45.3 m3·mol-1ChemAxon
Polarizability19.38 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on May 20, 2019 08:44 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates